DOCSLIB.ORG

(2006.01) Published: — A61K 9/00

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(2006.01) Published: — A61K 9/00 ll ( (51) International Patent Classification: Published: A61K9/46 (2006.01) A61K /20 (2006.01) — with international search report (Art. 21(3)) A61K 9/00 (2006.01) A61P 1/04 (2006.01) A61K9/06 (2006.01) A61K 31/58 (2006.01) A61K 9/10 (2006.01) (21) International Application Number: PCT/EP20 19/0687 18 (22) International Filing Date: 11 July 2019 ( 11.07.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 18182910.2 11 July 2018 ( 11.07.2018) EP (71) Applicant: MEDIZINISCHE UNIVERSITAT WIEN [AT/AT]; Spitalgasse 23, 1090 Wien (AT). (72) Inventors: ORGLER, Elisabeth; Leonhardstralk 3, 8010 Graz (AT). GASCHE, Christoph; Babenbergergasse 20, 3400 Klostemeuburg (AT). DABSCH, Stefanie; Alszeile 84, 1170 Wien (AT). (74) Agent: VOSSIUS & PARTNER (NO 31); Patentanwalte Rechtsanwalte mbB, Siebertstrasse 3, 81675 Munchen (PE). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available) : ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: GLUCOCORTICOIDS FOR THE TOPICAL TREATMENT OF AUTOIMMUNE GASTRITIS (57) Abstract: The present invention relates to compositions comprising one or more glucocorticoid(s)used in the topical treatment of autoimmune gastritisby delivering an effective amount of the glucocorticoid(s) to the topical area to be treated using a gastroretentive drug delivery system that releases the glucocorticoid(s) in a timely and locally controlled manner. Particularly, the topical area to be treated comprises or is the stomach mucosa, preferably the corpus and/or fundus of the stomach and the preferred glucocorticoid is budesonide. GLUCOCORTICOIDS FOR THE TOPICAL TREATMENT OF AUTOIMMUNE GASTRITIS Field of Invention The present invention relates to compositions comprising one or more glucocorticoid(s) used in the topical treatment of autoimmune gastritis by delivering an effective amount of the glucocorticoid(s) to the topical area to be treated using a controlled release drug delivery system that releases the glucocorticoid(s) in a timely and locally controlled manner. Particularly, the topical area to be treated comprises or is the mucosa of the stomach, preferably the mucosa of the corpus and/or fundus of the stomach and the preferred glucocorticoid is budesonide. Background of the Invention Autoimmune gastritis (AIG) is a chronic inflammatory disease of the stomach occurring in up to 8% of the general population and, as the name implies, is characterized by atrophy of the glands in the corpus mucosa caused by the cells of the body's own immune defense system, i.e. with the development of autoantibodies against parietal cells of the gastric body (Toh 2014). These parietal cell autoantibodies (PCA) destroy parietal cells of the corpus and fundus of the stomach leading to an atrophy of the mucosa. Parietal cells are epithelial cells located in the glands of the corpus and fundus but not in the antrum and produce hydrochloric acid and intrinsic factor (Kulnigg-Dabsch 2016). The acidification of the stomach is primarily managed by the gastritic H+/K+ ATPase, the proton pump, which is impaired in AIG (Toh et al, 2000). The decrease and final loss of the parietal cells during progression of the disease results in increased pH of the stomach and loss of intrinsic factor produced by parietal cells. Intrinsic factor is required for uptake of vitamin B I2. Consequently, vitamin B I2 deficiency is a known result of AIG (Kulnigg-Dabsch 2016). Thus, AIG is often associated with impaired absorption of vitamin B I2 and possibly other vitamin and mineral deficiencies, such as folate, and iron deficiency. Patients who developed vitamin B I2 deficiency will suffer from gastrointestinal and neurological complaints such as malabsorption, diarrhea, weight loss, glossitis, peripheral numbness, paresthesia with subsequent development of weakness, and ataxia (Kulnigg-Dabsch 2016). For classification and grading of chronic gastritis including AIG the updated Sydney classification system has been introduced (Dixon et al, 1996). This classification system is used to grade histological parameters, identify topographical distribution and, finally, make a statement about the etiopathogenesis of the gastritis. Of pathogenetic importance is, in the first instance, the differentiation between gastritis with and gastritis without H. pylori infection. In this context, the Sydney System differentiates between the atrophic gastritis of types A and B, wherein AIG is referred to the “A type” gastritis recognized as a corpus- restricted atrophic gastritis of autoimmune origin, and the “B type” represents the atrophic gastritis that is related to H.pylori infection (Dixon et al, 1996; Sipponen and Price, 201 1). The group of H. pylori-associated gastritis can be further subdivided into forms of gastritis whose morphological distribution patterns usually identify them as sequelae of H. pylori infection, while the group of gastritis unassociated with H. pylori, can be differentiated into autoimmune, chemically induced reactive gastritis, ex-H. pylori gastritis, Helicobacter heilmannii gastritis, Crohn's gastritis and a number of special forms of gastritis. (Stolte et al, 2001). In some cases, AIG does not cause any obvious signs and symptoms. However, some people may experience nausea, vomiting, a feeling of fullness in the upper abdomen after eating, or abdominal pain. The main manifestation of AIG is known to be pernicious anemia. The clinical signs and symptoms of anemia, irrespective of etiology, include shortness of breath, dizziness, tachycardia, lightheadedness, and decreased cognitive and physical function (Kulnigg-Dabsch 2016). In particular, a study by Hershko et al. (2006) further showed that the predominant hematolytic manifestation in patients with AIG is iron deficiency (ID) amenia, a nutritional deficiency caused by an imbalance of iron uptake and iron loss and affecting about 10 to 30 % of women in industrialized nations being in reproductive age. ID is either caused by increased loss of iron due to acute or chronic bleeding, such as gastrointestinal bleeding, augmented menstrual bleeding, or by low absorption of iron. Decreased iron absorption might be due to inflammation at the site of iron uptake, which is found in AIG, wherein the decrease of gastric acid and ascorbic acid contributing to the release of iron-protein-complexes and to reduction of ferric iron are well described (Hershko et al (2007); Aditi et al, (2012)). Symptoms of ID arise independently of amenia-related symptoms, and include fatigue, restless legs syndrome, brittle nails, hair loss, impaired immune function, and impaired wound healing. As for other chronic inflammatory diseases, patients suffering from chronic gastritis including AIG patients have a higher risk of developing carcinoid tumors and gastric adenocarcinomas within the chronically inflamed tissue (Torbenson et al., 2002). In this regard, AIG is considered a "precancerous" condition and it may be responsible for the development of gastric adenocarcinoma or carcinoids. Thereby, a precursor lesion may be induced by the chronic inflammation in AIG patients which may first lead to atrophy of the tissue in the fundus and/or the corpus and subsequently to intestinal metaplasia (Kulnigg-Dabsch 2016). Development of gastric cancer is also known from H. pylori-related gastritis, wherein a major characteristic of the infiltration with inflammatory cells is the typically severe corpus gastritis (Kulnigg-Dabsch 2016; Stolte et al., 2001). With respect to AIG patients, it is also surmised that unknown genetic, metabolic, or environmental triggers may lead to the adenocarcinoma, which is also known from colonic cancer (Correa 1988). The underlying genetic cause of AIG has not been fully identified yet. Studies suggest that the condition may be inherited in an autosomal dominant manner (Nafea 2014). Patients suffering from AIG are likely to have other autoimmune disorders including autoimmune thyroiditis, diabetes type I, Addison’s disease, and vitiligo. Diagnosis of AIG is made through a combination of clinical findings, such as certain blood tests and presence of other autoimmune conditions, and the collection of a biopsy of fundus and/or corpus obtained through endoscopy (Kulnigg-Dabsch 2016). Treatment is based on the signs and symptoms present in each person, but may include iron infusions, vitamin B I2 injections and endoscopic surveillance (Park et al, 2013; Kulnigg-Dabsch 2016). If pernicious anemia is already present at the time of diagnosis, vitamin B I2 injections may be recommended. Iron therapy approaches may include receiving periodic intravenous iron infusion to increase iron stores or a daily dose of oral ferrous glycine sulfate to meet daily iron requirements. In this context, it is recommended that levels of B I2 and iron are routinely monitored in patients suffering from and having suffered from AIG. In some cases, periodic endoscopy may also be recommended due to the increased risk of certain types of cancer (Park et al., 2013; Kulnigg-Dabsch 2016).
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Recent Advances in the Analysis of Steroid Hormones and Related Drugs
    ANALYTICAL SCIENCES MAY 2004, VOL. 20 767 2004 © The Japan Society for Analytical Chemistry Reviews Recent Advances in the Analysis of Steroid Hormones and Related Drugs Sándor GÖRÖG Gedeon Richter Ltd., P.O.B. 27, H-1475 Budapest, Hungary The development during the last 15 years and the state-of-the-art in the analysis of bulk steroid hormone drugs and hormone-like structures and pharmaceutical formulations made thereof are summarized. Other steroids (sterols, bile acids, cardiac glycosides, vitamins D) as well as biological-clinical aspects and pharmacokinetic and metabolic studies are excluded from this review. The state-of-the-art is summarized based on comparisons of monographs in the latest editions of the European Pharmacopoeia, United States Pharmacopoeia and the Japanese Pharmacopoeia. This is followed by sections dealing with new developments in the methodology for the fields of spectroscopic and spectrophotometric, chromatographic, electrophoretic and hyphenated techniques as well electroanalytical methods. The review is terminated by two problem-oriented sections: examples on impurity and degradation profiling as well as enantiomeric analysis. (Received January 14, 2004; Accepted February 2, 2004) 1 Introduction 767 4·3 Supercritical fluid chromatography (SFC) 2 Steroid Hormone Drugs in Pharmacopoeias 768 4·4 High-performance liquid chromatography 2·1 Assay of bulk drug materials (HPLC) and HPLC-MS 2·2 Related impurities test of bulk drug materials 5 Electrophoretic and Related Methods 776 2·3 Assay of steroid hormone formulations
    [Show full text]
  • United States Patent (10) Patent No.: US 9.447,027 B2 Milan Et Al
    US009447027B2 (12) United States Patent (10) Patent No.: US 9.447,027 B2 Milan et al. (45) Date of Patent: Sep. 20, 2016 (54) TREATING LONG QT SYNDROME 2004/O1972.71 A1* 10, 2004 Kunka et al. ................... 424/45 2006/0173058 A1* 8, 2006 Brown .................... CO7C 65/05 514,381 (75) Inventors: Es l, St. MS 2006/0173508 A1* 8, 2006 Stone ................. A61N 1,36085 aVId S. Peal, SomerV11 le. (US) 607/40 (73) Assignee: The General Hospital Corporation, FOREIGN PATENT DOCUMENTS Boston, MA (US) JP 11209328 A1 * 8, 1999 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 86 days. Nademanee, K. et al., Annals of the New York Academy of Sciences vol. 522, pp. 536-552, published 2006.* (21) Appl. No.: 13/822,264 Chouabe, C. et al., Molecular Pharmacology vol. 54 pp. 696-703, published 1998.* (22) PCT Filed: Oct. 20, 2011 Nishizawa, S., et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.e1-1167.e3, published Nov. 2009).* (86). PCT No.: PCT/US2011/057087 Nishizawa et al., (American Journal of Emergency Medicine vol. 27, pp. 1167.el -1167.e3, published Nov. 2009).* S 371 (c)(1), Nishizawa et al (American Journal of Emergency Medicine vol. 27. (2), (4) Date: Jul. 22, 2013 pp. 1167.e1-1167.e3, published Nov. 2009).* Anderson et al., “Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism.” Circula (87) PCT Pub. No.: WO2012/054718 tion 113:365-373, 2006, 10 pages.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich Et Al
    US 200400.58896A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0058896 A1 Dietrich et al. (43) Pub. Date: Mar. 25, 2004 (54) PHARMACEUTICAL PREPARATION (30) Foreign Application Priority Data COMPRISING AN ACTIVE DISPERSED ON A MATRIX Dec. 7, 2000 (EP)........................................ OO126847.3 (76) Inventors: Rango Dietrich, Konstanz (DE); Publication Classification Rudolf Linder, Kontanz (DE); Hartmut Ney, Konstanz (DE) (51) Int. Cl." ...................... A61K 31156; A61K 31/4439 (52) U.S. Cl. ........................... 514/171; 514/179; 514/338 Correspondence Address: (57) ABSTRACT NATH & ASSOCATES PLLC 1030 FIFTEENTH STREET, N.W. The present invention relates to the field of pharmaceutical SIXTH FLOOR technology and describes a novel advantageous preparation WASHINGTON, DC 20005 (US) for an active ingredient. The novel preparation is Suitable for 9 producing a large number of pharmaceutical dosage forms. (21) Appl. No.: 10/433,398 In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix com (22) PCT Filed: Dec. 6, 2001 posed of one or more excipients Selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid (86) PCT No.: PCT/EPO1/14307 eSter. US 2004/0058896 A1 Mar. 25, 2004 PHARMACEUTICAL PREPARATION 0008 Further subject matters are evident from the claims. COMPRISING AN ACTIVE DISPERSED ON A MATRIX 0009. The preparations for the purpose of the invention preferably comprise numerous individual units in which at least one active ingredient particle, preferably a large num TECHNICAL FIELD ber of active ingredient particles, is present in an excipient 0001. The present invention relates to the field of phar matrix composed of the excipients of the invention (also maceutical technology and describes a novel advantageous referred to as active ingredient units hereinafter).
    [Show full text]
  • Aclidinium for Use in Improving the Quality of Sleep in Respiratory Patients
    (19) & (11) EP 2 510 928 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 17.10.2012 Bulletin 2012/42 A61K 31/439 (2006.01) A61P 11/00 (2006.01) A61P 43/00 (2006.01) (21) Application number: 11382114.4 (22) Date of filing: 15.04.2011 (84) Designated Contracting States: • De Miquel Serra, Gonzalo AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 08980, Sant Feliú de Llobregat (ES) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Sala Peinado, María José PL PT RO RS SE SI SK SM TR 08980, Sant Feliú de Llobregat (ES) Designated Extension States: BA ME (74) Representative: Elzaburu Marquez, Alberto Elzaburu S.L.P. (71) Applicant: Almirall, S.A. Miguel Angel 21, 08022 Barcelona (ES) 28010 Madrid (ES) (72) Inventors: • García Gil, María Esther 08980, Sant Feliú de Llobregat (ES) (54) Aclidinium for use in improving the quality of sleep in respiratory patients (57) The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharma- ceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients. EP 2 510 928 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 510 928 A1 Description Field of the Invention 5 [0001] The invention relates to a novel use of aclidinium, which can be advantageously used to improve the quality of sleep in respiratory patients. Background of the Invention 10 [0002] Respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are a significant global health program, with an increasing incidence throughout the world.
    [Show full text]
  • Therapeutic Strategies for Allergic Diseases
    review articles Therapeutic strategies for allergic diseases Peter J. Barnes ............................................................................................................................................................................................................................................................................ Many drugs are now in development for the treatment of atopic diseases, including asthma, allergic rhinitis and atopic dermatitis. These treatments are based on improvements in existing therapies or on a better understanding of the cellular and molecular mechanisms involved in atopic diseases. Although most attention has been focused on asthma, treatments that inhibit the atopic disease process would have application to all atopic diseases, as they often coincide. Most of the many new therapies in development are aimed at inhibiting components of the allergic in¯ammatory response, but in the future there are real possibilities for the development of preventative and even curative treatments. Atopic diseases* account for a large proportion of health care develop inhibitors of speci®c in¯ammatory mediators and, because spending in industrialized countries, as these conditions are many mediators have been implicated in atopic diseases, there are common, persistent and currently incurable. There has been an several such drugs in development. Cytokines have a critical role in enormous investment by the pharmaceutical companies in the the allergic in¯ammatory process and I review drugs that inhibit the
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • (12) United States Patent (Lo) Patent No.: US 8,480,637 B2
    111111111111111111111111111111111111111111111111111111111111111111111111 (12) United States Patent (lo) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent : Jul. 9, 2013 (54) NANOCHANNELED DEVICE AND RELATED USPC .................. 604/264; 907/700, 902, 904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al . .................... 216/56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al . ................... 424/422 Sharath Hosali, Austin, TX (US); Ryan 5,770,076 A 6/1998 Chu et al ....................... 210/490 5,798,042 A 8/1998 Chu et al ....................... 210/490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4/1999 Keller et al . .................. 510/483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al . ........................ 210/490 5,948,255 A * 9/1999 Keller et al . ............. 210/321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 11/1999 Chu et al ......................... 516/41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al ....................... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this WO WO 2004/036623 4/2004 WO WO 2006/113860 10/2006 patent is extended or adjusted under 35 WO WO 2009/149362 12/2009 U.S.C. 154(b) by 612 days.
    [Show full text]
  • Inhalation Composition Containing Aclidinium for Treatment of Asthma and Chronic Obstructive Pulmonary Disease
    (19) & (11) EP 2 100 599 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 16.09.2009 Bulletin 2009/38 A61K 9/14 (2006.01) A61K 9/72 (2006.01) A61K 31/46 (2006.01) A61K 45/06 (2006.01) (2006.01) (21) Application number: 08382010.0 A61K 9/00 (22) Date of filing: 13.03.2008 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Lamarca Casado, Rosa HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT 08018, Barcelona (ES) RO SE SI SK TR • De Miquel Serra, Gonzalo Designated Extension States: 08029, Barcelona (ES) AL BA MK RS (74) Representative: Elzaburu Marquez, Alberto (71) Applicant: Laboratorios Almirall, S.A. Elzaburu S.L.P., 08022 Barcelona (ES) Miguel Angel, 21, 2° 28010 Madrid (ES) (54) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease (57) This invention relates to a novel dosage for aclidinium and to novel methods and formulations for the treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD), using aclidinium. EP 2 100 599 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 100 599 A1 Description [0001] This invention relates to a novel dosage for aclidinium and to novel methods and formulations for the treatment of respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD), using aclidinium. 5 BACKGROUND [0002] Aclidinium bromide is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]oc- tane bromide, described in, e.g., WO 0104118.
    [Show full text]